Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;22(5):353-9.
doi: 10.1097/MED.0000000000000184.

Leptin applications in 2015: what have we learned about leptin and obesity?

Olivia M Farr  1 , Anna Gavrieli, Christos S Mantzoros
Affiliations
Review

Leptin applications in 2015: what have we learned about leptin and obesity?

Olivia M Farr et al. Curr Opin Endocrinol Diabetes Obes. 2015 Oct.

Abstract

Purpose of review: To summarize previous and current advancements for leptin therapeutics, we described how leptin may be useful in leptin deficient states such as lipodystrophy, for which leptin was recently approved, and how it may be useful in the future for typical obesity.

Recent findings: The discovery of leptin in 1994 built the foundation for understanding the pathophysiology and treatment of obesity. Leptin therapy reverses morbid obesity related to congenital leptin deficiency and appears to possibly treat lipodystrophy, a finding which has led to the approval of leptin for the treatment of lipodystrophy in the USA and Japan. Typical obesity, on the other hand, is characterized by hyperleptinemia and leptin tolerance. Thus, leptin administration has proven ineffective for inducing weight loss on its own but could possibly be useful in combination with other therapies or for weight loss maintenance.

Summary: Leptin is not able to treat typical obesity; however, it is effective for reversing leptin deficiency-induced obesity and is possibly useful in lipodystrophy. New mechanisms and pathways involved in leptin resistance are continuously discovered, whereas the development of new techniques and drug combinations which may improve leptin's efficacy and safety regenerate the hope for its use as an effective treatment for typical obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Leptin dimerizes the leptin receptor (LepR) and activates a number of intracellular signaling molecules
JAK2 phosphorylates three tyrosine sites on the LepR and activates STAT3, which inhibits melanocortin, PI3K, which in turn acts on the insulin receptor, AKT, and mTOR pathways, and STAT5, whose function is not yet well defined. At Tyr985, SOCS3 and SHP2 both feedback to inhibit JAK2, and SHP2 activates ERK pathways. At Tyr1077, STAT5 activation leads to gene expression changes. At Tyr1138, STAT3 alters gene expression and activates SOCS3, which feeds back to inhibit JAK2.
See this image and copyright information in PMC

References

    1. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432. - PubMed
    1. Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409–1421. - PMC - PubMed
    1. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93–100. - PMC - PubMed
    1. Broberger C, Johansen J, Johansson C, et al. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A. 1998;95:15043–15048. - PMC - PubMed
    1. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88:131–141. - PubMed

Publication types